Pharmaceutical Products​

    Research

    TLR4 mediated immune
    boosting

    TLR4 mediating immune boosters are not well known until now, but in fact, TLR4 mediating substances have been used for a long time and have been safe. For example, polysaccharides in mushrooms (such as reishi mushrooms) mediate TLR4, and Fucoidan also mediates TLR4. Therefore, it can be seen that the polysaccharide that mediates TLR4 is very safe.
    Some consider TLR4 to be dangerous because LPS that binds to TLR4 causes very strong inflammation. However, LPS does not bind directly to TLR4, but to MD2, and this complex binds to TLR4. In addition, it can be seen that even a small change in the structure results in a very low activity. Therefore, it can be seen that not all TLR4 binding ligands are dangerous, but they range from very safe to very dangerous.

    Enhance Phagocytosis

    BioBRB’s polysaccharide can induce phagocytosis very rapidly, which means that the MyD88 signaling pathway that secretes inflammatory cytokines is converted into a relatively safe TRIF pathway signaling. In addition, when phagocytosis occurs, the surrounding substances are also phagocytosed, so it has the effect of phagocytosing of the substances causing inflammation.

    Enhance Phagosomal
    degradation

    Another characteristic of BioBRB is that when phagocytosis occurs, the subsequent degradation process is very rapid. Inflammation quickly subsides.

    Th1 inducing
    Food ingredients

    Phagocytosis is an important process leading to adaptive immunity and, in particular, relatively induction of Th1 immunity occurs. This means that this immunosuppressant has both anticancer and antiallergic effects.

    CIN(cancer induced neutropenia)

    Currently, we are focusing on cancer induced neutropenia in drug development. Although neutropenia is a very important problem for cancer patients, decades have passed since the first drug was developed, but there is still an unmet need.
    MOA
    Currently, the treatment for neutropenia is G-CSF, which increases the production of neutrophils in the bone marrow to improve neutropenia caused by cytotoxic anticancer drugs, but there is still an unmet need. On the other hand, Toloran4 does not have the ability to increase neutrophils in the bone marrow, and has a mechanism to alleviate the symptoms of neutropenia by reducing inflammation. It is expected to have sufficient efficacy on its own, and its mechanism of action is complementary to that of the existing G-CSF.

    Phagocytosis (endocytosis)
    for CIN

    Phagocytosis plays the most important role in the regulation of inflammation. In other words, if phagocytosis removes pro-inflammatory substances quickly enough, inflammation above normal levels does not occur. However, if the pro-inflammatory substance is not sufficiently removed, the substance stays in the cell membrane longer and the inflammatory signal becomes stronger. Therefore, the safest way to reduce inflammation is to promote phagocytosis, and this function also helps to improve neutropenia.